7 analysts rate Cullinan Oncology NASDAQ: CGEM as "Buy" with a 12-month target of $32.00.
7 analysts give Cullinan Oncology (NASDAQ: CGEM) an average "Buy" rating with a consensus 12-month price target of $32.00. The firm, focused on oncology therapies for cancer patients, has experienced recent support from analysts like BTIG Research, Stifel Nicolaus, Jonestrading, and Wedbush. The company last reported earnings per share of ($0.54), exceeding consensus estimates.
May 19, 2024
3 Articles